Evidence map›Paper›PMID 39521757›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

ETS1 promotes cisplatin resistance of NSCLC cells by promoting GRP78 transcription.

Cong Liu, Junguang Jiang, Junfang Luo, Yang Zhang, Chao Yang, Jiang Shi

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cong LiuDepartment of Geriatric Respiratory & Sleep, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Junguang JiangDepartment of Geriatric Respiratory & Sleep, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Junfang LuoDepartment of Geriatric Respiratory & Sleep, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Yang ZhangDepartment of Geriatric Respiratory & Sleep, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Chao YangDepartment of Geriatric Respiratory & Sleep, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Jiang ShiDepartment of Geriatric Respiratory & Sleep, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. shijiangdoc@163.com.

Funding

Province Ministry Joint Construction Project of Henan Province Medical Science and Technology Plan SBGJ202302065
6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is a common malignant tumor characterized by rapid growth and invasive power. Glucose regulatory protein 78 (GRP78) is important in cancer cell progression. Here, this study aimed to explore the effect and mechanism of GRP78 on cisplatin (DDP) resistance of NSCLC cells. qRT-PCR and Western blot detected the expression of genes and proteins. Flow cytometry was used to analyze endoplasmic reticulum stress (ERS) induced by DDP in NSCLC. Cell proliferation and apoptosis were examined using cell counting kit-8 (CCK8), cell cloning, and flow cytometry, respectively. Chromatin immunoprecipitation assay (CHIP) and dual-luciferase reporter assays were performed to determine the binding of ETS1 and GRP78 promoter. Mouse xenograft models were constructed for in vivo analysis. ERS was induced by DDP in NSCLC cells. GRP78 were upregulated in DDP-resistant NSCLC tissues, and knockdown of GRP78 suppressed DDP resistance, clone formation, promoted apoptosis, and inhibited ERS in DDP-resistant NSCLC cells. ETS1 knockdown repressed GRP78 expression and NSCLC tumor growth. Interestingly, ETS1 played a role in DDP-resistant NSCLC via GRP78. ETS1 inhibits cisplatin sensitivity of NSCLC cells by promoting GRP78 transcription.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungCisplatinDrug Resistance, NeoplasmHeat-Shock ProteinsLung NeoplasmsProto-Oncogene Protein c-ets-1A549 CellsAnimalsApoptosisCell Line, TumorCell ProliferationEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressFemaleGene Expression Regulation, NeoplasticAntineoplastic AgentsCisplatinEndoplasmic Reticulum Chaperone BiPETS1 protein, humanHeat-Shock ProteinsHSPA5 protein, humanHspa5 protein, mouseProto-Oncogene Protein c-ets-1Cisplatin resistanceEndoplasmic reticulum stressETS1GRP78NSCLC

Identifiers

PMID39521757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.